US · ANL
Adlai Nortye Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Grand Cayman KY1-1104
- Website
- adlainortye.com
Price · as of 2024-12-31
$15.50
Market cap 245.52M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $21.13 | +36.32% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | $7.65 | $2.52 | $0.00 | ||
| 2024 | $2.31 | $21.13 |
AI valuation
Our deep-learning model estimates Adlai Nortye Ltd.'s (ANL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $21.13
- Current price
- $15.50
- AI upside
- +36.32%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ANL | Adlai Nortye Ltd. | $15.50 | 245.52M | +36% | — | — | — | -0.47 | 0.97 | — | 0.19 | — | 0.97 | 0.00% | — | — | -98.90% | -2580.88% | -51.49% | 1.07 | -28.22 | 1.41 | 1.37 | 0.70 | -6829.00% | -10000.00% | -855.00% | -211.30% | -1.14 | -2444.23% | 0.00% | 0.00% | 0.00% | 0.17 | 0.17 | — | -10.34 |
| ADTX | Aditxt, Inc. | $0.46 | 9.84K | +128,310,097% | +775,435,055% | — | +4,369,268,359% | 0.00 | 0.02 | 1.28 | 30.55 | -0.01 | 0.02 | -367.95% | -20796.36% | -25708.85% | -276.39% | 7.12% | -89.79% | 0.78 | -3.78 | 0.09 | 35.64 | -0.23 | 3863.00% | -7923.00% | -984.00% | -9785.19% | -0.72 | 4.28% | 0.00% | 0.00% | 8689.62% | 29.64 | 49.27 | -6164.42 | -10.97 |
| AIMD | Ainos, Inc. | $1.64 | 7.91M | +1,477% | -27% | — | +6,696% | -1.56 | 1.50 | 1120.96 | -3.32 | — | -2.82 | -153.73% | -66772.17% | -71702.26% | -74.38% | -53.08% | -49.00% | 0.77 | -22.45 | 1.10 | 0.98 | -0.86 | -5357.00% | -8302.00% | 2176.00% | -25.09% | -1.47 | -22.36% | 0.00% | 0.00% | 0.00% | -2.26 | -5.38 | 1512.06 | -3.08 |
| APLM | Apollomics, Inc. | $20.21 | 22.3M | +737% | +1,097% | — | +18,417% | -0.11 | 1.22 | 29.90 | 0.07 | — | 1.89 | 100.00% | -21280.81% | -27201.01% | -233.67% | -2034.57% | -157.28% | 0.20 | -235.40 | 1.39 | 1.34 | 0.21 | -7724.00% | -7588.00% | -3343.00% | -485.92% | -3.88 | -1389.04% | 0.00% | 0.00% | 0.00% | 0.07 | 0.10 | -14.54 | -84.82 |
| BLRX | BioLineRx Ltd. | $2.83 | 12.31M | +2,367% | — | — | — | -27.55 | 18.87 | 8.78 | 63.67 | — | 84.33 | 67.99% | -70.52% | -31.86% | -69.11% | 441.68% | -17.93% | 1.12 | -2.23 | 1.76 | 1.52 | 1.18 | -8723.00% | 50292.00% | 9178.00% | -17.29% | -2.85 | 950.70% | 0.00% | 0.00% | 1.08% | -12.22 | -5.68 | 8.62 | -9.02 |
| GOVX | GeoVax Labs, Inc. | $1.60 | 1.62M | — | +969% | — | — | -0.35 | 1.76 | 2.24 | -0.14 | — | 1.78 | 97.59% | -635.83% | -631.98% | -462.31% | 4381.85% | -286.62% | 0.00 | -1176.34 | 2.55 | 1.98 | 0.22 | -5284.00% | — | -209.00% | -278.43% | -7.94 | 4303.75% | 0.00% | 0.00% | 0.00% | -0.13 | -0.14 | 0.85 | -29.47 |
| ICU | SeaStar Medical Holding C… | $2.76 | 7.7M | — | — | — | — | -0.27 | -3.10 | 50.20 | -0.23 | — | -3.10 | 100.00% | -13216.30% | -18392.59% | 309.35% | 425.16% | -607.76% | -0.26 | -73.12 | 0.55 | 0.28 | 0.05 | -7809.00% | — | 5563.00% | -236.21% | -2.34 | 381.44% | 0.00% | 0.00% | 149.78% | -0.31 | -0.35 | 40.98 | -54.76 |
| LPCN | Lipocine Inc. | $9.96 | 55.3M | +2,939% | -66% | -60% | — | 2199.00 | 0.87 | 1.64 | 2.93 | — | 0.87 | 100.00% | -10.31% | 0.07% | 0.04% | 92.79% | 0.04% | 0.00 | — | 14.75 | 14.38 | 5.57 | -9995.00% | -49280.00% | -8896.00% | -7.14% | -0.81 | 113.94% | 0.00% | 0.00% | 7.81% | 2.83 | 2.49 | -0.29 | -3.70 |
| OSRH | OSR Holdings, Inc. | $0.41 | 10.58M | — | — | — | — | -5.08 | -1.58 | — | -3.39 | — | -1.58 | 0.00% | — | — | -15.54% | -21.87% | -10.39% | -0.27 | 81.95 | 0.07 | 0.01 | -0.48 | -85209.00% | — | 16722.00% | -21.32% | -0.33 | -15.79% | 0.00% | 0.00% | 0.00% | -3.39 | -5.47 | — | -12.68 |
| THAR | Tharimmune, Inc. | $5.12 | 202.4M | — | — | — | — | -0.16 | 1.51 | — | 0.13 | — | 1.51 | 0.00% | — | — | -233.69% | 613.15% | -166.32% | 0.00 | -908.64 | 1.54 | 1.47 | 0.29 | -9121.00% | — | 4934.00% | -553.30% | -4.52 | 537.61% | 0.00% | 0.00% | 0.00% | 0.13 | 0.15 | — | -24.00 |
About Adlai Nortye Ltd.
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
- CEO
- Yang Lu
- Employees
- 123
- Beta
- -1.88
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $15.50) − 1 = — (DCF, example).